Khaled Musallam/LinkedIn
Nov 20, 2025, 16:47
Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Priviliged to be working with my friend Prof.Humaid Al-Shamsi to build on the strong foundations of BCI and lead the expansion of hematology services across the network, including dedicated programs in both classical (benign) and malignant hematology, and advanced cell and gene therapies through innovative clinical trials and strategic international partnerships with industry innovators.”

Stay updated with Hemostasis Today.
-
Jul 17, 2026, 20:19Thomas Muenzel: Proud to Deliver the Sylviane Lévy-Toledano Memorial Plenary Keynote Lecture at ISTH 2026
-
Jul 17, 2026, 20:16Karin Leiderman: Proud of Jamie Madrigal for Receiving the JTH Editors’ Award
-
Jul 17, 2026, 20:14Lily Bull: Presenting New Research and Building Connections at ISTH 2026
-
Jul 17, 2026, 20:12Modern Concepts in Traumatic Disseminated Intravascular Coagulation – JTH
-
Jul 17, 2026, 20:10Nahid A. Qushmaq: Science, Collaboration, and Inspiration at ISTH 2026
-
Jul 17, 2026, 18:20Sarah Jones: Bringing Vessel-on-a-Chip Research to ISTH 2026
-
Jul 17, 2026, 18:06Virginia Barras Sánchez: United by a Commitment to Hemophilia at ISTH 2026
-
Jul 17, 2026, 17:53Micah Grey: Shaping the Future of Hematology at ISTH 2026
-
Jul 17, 2026, 17:32Vasiliki Danilatou: Advancing β-Thalassemia Research at ISTH 2026